Company news
Revelation Biosciences, Inc. (NASDAQ:REVB) news
Every Revelation Biosciences, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Revelation Biosciences Selects Avance Clinical as CRO for Phase 2/3 TITAN Study
August 19, 2026
Independent Market Assessment Results Show $94 Billion Total Addressable Market for Gemini in Stage 2 and Stage 3 Acute Kidney Injury
August 3, 2026
Revelation Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
July 21, 2026
Revelation Biosciences Announces Adoption of Stockholder Rights Plan
July 10, 2026
Revelation Biosciences Expands Acute Kidney Injury Advisory Board
June 1, 2026
Revelation Biosciences, Inc. Releases Corporate Update Letter to Stockholders
May 11, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three Months Ended March 31, 2026
May 7, 2026
Revelation Biosciences Announces Formation of Acute Kidney Injury Advisory Board
April 6, 2026
REMINDER: Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
March 24, 2026
Revelation Biosciences to Host Fireside Chat at 38th Annual Roth Conference
March 19, 2026
Revelation Biosciences, Inc. Announces Financial Results For the Three and Twelve Months Ended December 31, 2025
February 26, 2026
Revelation Biosciences Inc. Announces 1-for-4 Reverse Stock Split Effective January 28, 2026
January 26, 2026
Revelation Biosciences Inc. Announces Exercise of Warrants for $11 Million in Gross Proceeds
January 23, 2026
Revelation Biosciences Reaches Agreement with FDA on Gemini Approval Pathway for AKI
January 21, 2026
Revelation Biosciences Inc. to Present at The International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2026)
January 14, 2026
Revelation Biosciences Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
January 12, 2026
Revelation Biosciences Announces Initiation of GMP Manufacturing of GEMINI and Placebo to Support Later Stage Clinical Development
January 7, 2026
Revelation Biosciences Has Reached A Quorum For Its December 3, 2025 Special Meeting
December 1, 2025
Revelation Biosciences On Track for End-of-Phase 1 Meeting With FDA Later This Year
November 20, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Nine Months Ended September 30, 2025
November 6, 2025
Revelation Biosciences Inc. Announces Cancellation of Adjournment of October 29, 2025 Special Meeting of Stockholders and New Record Date
October 29, 2025
Revelation Biosciences Inc. Announces Adjournment of October 15, 2025 Special Meeting of Stockholders to October 29, 2025
October 15, 2025
Revelation Biosciences Inc. Announces Exercise of Warrants for $9.6 Million in Gross Proceeds
September 11, 2025
Revelation Biosciences Announces Special Webcast to Review Positive Top-line Clinical Data
September 10, 2025
Reminder - Webcast/Conference Call to Discuss Fantastic PRIME Phase 1b Top-line Data
September 9, 2025
Revelation Biosciences Announces Groundbreaking Top-line Results from PRIME Clinical Study
September 9, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2025
August 8, 2025
Revelation Biosciences, Inc. Congratulates Its Former Chairman of the Board, George Tidmarsh, on His Appointment as the Head of the FDA C...
July 24, 2025
Revelation Biosciences Inc. Completes Dosing of Patients in PRIME Study
July 16, 2025
Revelation Biosciences Inc. Announces 1-for-3 Reverse Stock Split Effective July 7, 2025
July 1, 2025
Revelation Biosciences, Inc. Announces Closing of $4 Million Public Offering
May 29, 2025
Revelation Biosciences, Inc. Announces Pricing of $4 Million Public Offering
May 29, 2025
Revelation Biosciences Announces Retirement of George Tidmarsh, MD, PhD from Board of Directors
May 23, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three Months Ended March 31, 2025
May 8, 2025
Revelation Biosciences to Develop Gemini for Infection in Severe Burn Patients
April 29, 2025
Gemini Priming Attenuates Inflammation in Human Peripheral Blood Mononuclear Cells
March 17, 2025
Revelation Biosciences to Host Fireside Chat at 37th Annual Roth Conference
March 13, 2025
Revelation Biosciences, Inc. Announces Financial Results for the Three and Twelve Months Ended December 31, 2024
March 6, 2025
Revelation Biosciences Doses First Patient in PRIME Phase 1b Clinical Study of Gemini in CKD Patients
February 26, 2025
Revelation Biosciences, Inc. Receives Continued NASDAQ Listing Approval
February 24, 2025
Revelation Biosciences Inc. Announces 1-for-16 Reverse Stock Split Effective January 28, 2025
January 24, 2025
Revelation Biosciences Starts its PRIME Phase 1b Clinical Study of Gemini in CKD Patients
January 21, 2025
Revelation Biosciences Inc. Reminds You to Vote for the Special Meeting on January 17, 2025
January 13, 2025
Nasdaq Grants Revelation Biosciences Inc. Continued Listing
January 6, 2025
Revelation Biosciences Inc. Appoints Joseph A. Bellanti, M.D. to Scientific Advisory Board
December 6, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 2b Study to Assess Efficacy of Intranasal REVTx-99 for The Prevention of H3N2...
December 1, 2021
Revelation Biosciences Inc. Announces Creation and Appointments to Scientific Advisory Board
November 29, 2021
Revelation Biosciences Inc. Announces Initiation of a Phase 1b Clinical Study of REVTx-99 for the Experimental Treatment of Allergic Rhin...
November 15, 2021
Revelation Biosciences Inc. Receives Approval to Begin a Phase 1b Clinical Study of REVTx-99 as an Experimental Treatment for Allergic Rh...
October 4, 2021
Revelation Biosciences Inc. Receives Approval to Initiate Phase 2b Viral Challenge Study of REVTx 99, an Experimental Prophylactic Treatm...
September 28, 2021